162 related articles for article (PubMed ID: 34600097)
1. Lactobacillus rhamnosus induces CYP3A and changes the pharmacokinetics of verapamil in rats.
Liu J; Cheng Y; Zhang Y; Huang S; Liu Z; Wang X
Toxicol Lett; 2021 Nov; 352():46-53. PubMed ID: 34600097
[TBL] [Abstract][Full Text] [Related]
2. Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats.
Hu N; Xie S; Liu L; Wang X; Pan X; Chen G; Zhang L; Liu H; Liu X; Liu X; Xie L; Wang G
Drug Metab Dispos; 2011 Mar; 39(3):419-25. PubMed ID: 21135265
[TBL] [Abstract][Full Text] [Related]
3. Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin.
Hong SP; Chang KS; Koh YY; Choi DH; Choi JS
Arch Pharm Res; 2009 Oct; 32(10):1447-52. PubMed ID: 19898809
[TBL] [Abstract][Full Text] [Related]
4. Effect of
Toscano M; De Grandi R; Stronati L; De Vecchi E; Drago L
World J Gastroenterol; 2017 Apr; 23(15):2696-2704. PubMed ID: 28487606
[TBL] [Abstract][Full Text] [Related]
5. Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats.
Choi DH; Li C; Choi JS
Eur J Drug Metab Pharmacokinet; 2009; 34(3-4):163-8. PubMed ID: 20166433
[TBL] [Abstract][Full Text] [Related]
6. Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats.
Chung JH; Choi DH; Choi JS
Biopharm Drug Dispos; 2009 Mar; 30(2):90-3. PubMed ID: 19226653
[TBL] [Abstract][Full Text] [Related]
7. Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits.
Kim HJ; Choi JS
Biopharm Drug Dispos; 2005 Oct; 26(7):295-300. PubMed ID: 16013069
[TBL] [Abstract][Full Text] [Related]
8.
Spacova I; Van Beeck W; Seys S; Devos F; Vanoirbeek J; Vanderleyden J; Ceuppens J; Petrova M; Lebeer S
Gut Microbes; 2020 Nov; 11(6):1729-1744. PubMed ID: 32522072
[TBL] [Abstract][Full Text] [Related]
9. The effect of Lactobacillus rhamnosus hsryfm 1301 on the intestinal microbiota of a hyperlipidemic rat model.
Chen D; Yang Z; Chen X; Huang Y; Yin B; Guo F; Zhao H; Zhao T; Qu H; Huang J; Wu Y; Gu R
BMC Complement Altern Med; 2014 Oct; 14():386. PubMed ID: 25300818
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin.
Choi DH; Chung JH; Choi JS
Eur J Clin Pharmacol; 2010 Mar; 66(3):285-90. PubMed ID: 20012601
[TBL] [Abstract][Full Text] [Related]
11. Probiotic Lactobacillus rhamnosus GG (LGG) restores intestinal dysbacteriosis to alleviate upregulated inflammatory cytokines triggered by femoral diaphyseal fracture in adolescent rodent model.
Chen JF; Zhuang Y; Jin SB; Zhang SL; Yang WW
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):376-389. PubMed ID: 33506927
[TBL] [Abstract][Full Text] [Related]
12. Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil.
Choi DH; Shin WG; Choi JS
Eur J Clin Pharmacol; 2008 May; 64(5):445-9. PubMed ID: 18193210
[TBL] [Abstract][Full Text] [Related]
13. Anti-obesity effect of Lactobacillus rhamnosus LS-8 and Lactobacillus crustorum MN047 on high-fat and high-fructose diet mice base on inflammatory response alleviation and gut microbiota regulation.
Wang T; Yan H; Lu Y; Li X; Wang X; Shan Y; Yi Y; Liu B; Zhou Y; Lü X
Eur J Nutr; 2020 Sep; 59(6):2709-2728. PubMed ID: 31659451
[TBL] [Abstract][Full Text] [Related]
14. Lactobacillus rhamnosus HDB1258 modulates gut microbiota-mediated immune response in mice with or without lipopolysaccharide-induced systemic inflammation.
Han SK; Shin YJ; Lee DY; Kim KM; Yang SJ; Kim DS; Choi JW; Lee S; Kim DH
BMC Microbiol; 2021 May; 21(1):146. PubMed ID: 33985438
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive Probiotic
Gao G; Ma T; Zhang T; Jin H; Li Y; Kwok LY; Zhang H; Sun Z
Front Immunol; 2021; 12():772532. PubMed ID: 34970262
[TBL] [Abstract][Full Text] [Related]
16. A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human.
Wang J; Xia S; Xue W; Wang D; Sai Y; Liu L; Liu X
Eur J Pharm Sci; 2013 Nov; 50(3-4):290-302. PubMed ID: 23916407
[TBL] [Abstract][Full Text] [Related]
17. Eczema-protective probiotic alters infant gut microbiome functional capacity but not composition: sub-sample analysis from a RCT.
Murphy R; Morgan XC; Wang XY; Wickens K; Purdie G; Fitzharris P; Otal A; Lawley B; Stanley T; Barthow C; Crane J; Mitchell EA; Tannock GW
Benef Microbes; 2019 Feb; 10(1):5-17. PubMed ID: 30574802
[TBL] [Abstract][Full Text] [Related]
18. Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats.
Choi JS; Burm JP
Arch Pharm Res; 2008 Sep; 31(9):1200-4. PubMed ID: 18806964
[TBL] [Abstract][Full Text] [Related]
19. Effects of liver fibrosis on verapamil pharmacokinetics in rats.
Chen M; Xu D; Hu XL; Wang H
Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):287-94. PubMed ID: 17973928
[TBL] [Abstract][Full Text] [Related]
20. Effect of Huang-Lian-Jie-Du-Decoction on pharmacokinetics of verapamil in rats.
Xie SS; Hu N; Jing XY; Liu XD; Xie L; Wang GJ; Liu CH
J Pharm Pharmacol; 2010 Apr; 62(4):440-7. PubMed ID: 20604832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
